Argenx
ARGX
#535
Rank
S$56.30 B
Marketcap
S$909.82
Share price
-2.31%
Change (1 day)
17.77%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): S$11.52

According to Argenx 's latest financial reports the company's current EPS (TTM) is S$11.35. In 2024 the company made an earnings per share (EPS) of S$17.81 an increase over its 2023 EPS that were of S-$6.60.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$11.52-35.28%
2024S$17.81-369.77%
2023S-$6.60-60.46%
2022S-$16.6963.33%
2021S-$10.22-40.37%
2020S-$17.14183.47%
2019S-$6.05123.09%
2018S-$2.7154.93%
2017S-$1.7514.07%
2016S-$1.5313.05%
2015S-$1.36-36.34%
2014S-$2.13209.04%
2013S-$0.69-33.99%
2012S-$1.04185.59%
2011S-$0.37